EAN News

The EAN is deeply saddened to learn of the passing of Christopher Gardner-Thorpe, a founder member and former Fellow of the EAN

Key regulatory milestones, pharmacovigilance updates and innovation initiatives from the EMA Annual Report 2025 that are most pertinent to the neurological community

New EAN President, Prof. Kailash Bhatia, discusses his priorities for the EAN, the role of AI in neurology, and more, in this EAN TV interview from the EAN Congress 2026

One day ahead of the EAN Congress 2026 in Geneva, neurologists and researchers from across Europe took part in the annual EAN Guidelines Workshop

This month’s selected paper collected European-ancestry data from several large consortia and cohorts for a major consensus meta-analysis of genome-wide association studies for Alzheimer's disease and related dementias.

Each month the eanNews editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for July 2026.

We congratulate the winners of the EAN Tournament at the 12th Congress of the European Academy of Neurology in Geneva!

EAN Communications Committee member Agne Straukiene talks to Prof. Riccardo Soffietti, who delivered the Camillo Golgi Lecture at the 12th Congress of the European Academy of Neurology

Dementia imposes huge cost across 30 high-income European countries, with families and unpaid informal carers carrying much of the burden, according to the COIN-Eu study published in the Journal of Alzheimer’s Disease.

eanNews Editor Benedetta Bodini talks to Prof. Daniela Berg, who delivered the Moritz Romberg Lecture at the EAN Congress 2026

Thanks to this year's group of authors who gave their time, attention, and expertise to report on some of the most relevant sessions of this year’s congress.

This EAN TV Session, organised by the Resident & Research Fellow Section, explored how AI is transforming neurology

This thought-provoking EAN TV session brought together leading African neurology experts, exploring the continent’s evolving neurological health challenges.

A full audience for this session reflected the growing interest in CIDP, autoimmune nodopathies and complement-targeted therapies.

Can someone have Alzheimer's disease before they develop symptoms? This fascinating workshop explored why the answer depends on how we define the disease—and why that debate matters more than ever in the era of disease-modifying therapies.